Compare MLM & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLM | INSM |
|---|---|---|
| Founded | 1993 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0B | 33.5B |
| IPO Year | 1994 | 2000 |
| Metric | MLM | INSM |
|---|---|---|
| Price | $662.20 | $155.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 24 |
| Target Price | ★ $678.87 | $192.27 |
| AVG Volume (30 Days) | 397.1K | ★ 2.7M |
| Earning Date | 02-11-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 18.97 | N/A |
| Revenue | ★ $6,903,000,000.00 | $447,022,000.00 |
| Revenue This Year | $2.22 | $53.83 |
| Revenue Next Year | $7.93 | $138.44 |
| P/E Ratio | $34.50 | ★ N/A |
| Revenue Growth | 17.84 | ★ 30.34 |
| 52 Week Low | $441.95 | $60.40 |
| 52 Week High | $668.83 | $212.75 |
| Indicator | MLM | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 38.30 |
| Support Level | $639.16 | $150.80 |
| Resistance Level | $659.54 | $165.47 |
| Average True Range (ATR) | 14.89 | 6.33 |
| MACD | 0.43 | 0.20 |
| Stochastic Oscillator | 70.76 | 33.36 |
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2024, Martin Marietta sold 191 million tons of aggregates. Martin Marietta's most important markets include Texas, North Carolina, Colorado, California, and Georgia, accounting for most of its sales. The company also uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.